SLC5A2 and type 1 diabetes mellitus: Another semi-mechanistic exposure-response model (Perkins et al., 2020; Johnston et al., 2021) has been used to successfully predict the time-course and dose-related changes in HbA1c levels with SGLT-2 inhibitor treatment in patients with T1D, which boosts confidence in the current analysis.